Zoetis (ZTS) Restructuring Costs (2012 - 2026)

Zoetis (ZTS) posted quarterly Restructuring Costs of $20.0 million for Q1 2026, up 25.0% quarter-over-quarter from $16.0 million in Q4 2025.

Zoetis (ZTS) Restructuring Costs (2012 - 2026) Analysis & Trends

Zoetis (ZTS) has reported Restructuring Costs for 15 consecutive years, with $20.0 million the latest figure, recorded in Q1 2026.

In Q1 2026, Restructuring Costs changed N/A year-over-year to $20.0 million; the TTM figure through Mar 2026 stood at $70.0 million (up 42.86% YoY), while the FY2025 annual figure was $49.0 million, down 7.55% from the prior year.
Restructuring Costs improved to $20.0 million in Q1 2026 per ZTS's latest filing, from $16.0 million in the prior quarter.
Across five years, Restructuring Costs topped out at $42.0 million in Q2 2024 and bottomed at -$3.0 million in Q4 2022.
Historically, Restructuring Costs has averaged $11.4 million across 5 years, with a median of $7.0 million in 2022.
Annual changes were most pronounced in 2022 — Restructuring Costs tumbled 175.0% — and 2023, when it soared 950.0%.
Zoetis' Restructuring Costs stood at -$3.0 million in 2022, then jumped by 366.67% to $8.0 million in 2023, then slumped by 75.0% to $2.0 million in 2024, then jumped by 700.0% to $16.0 million in 2025, then climbed by 25.0% to $20.0 million in 2026.
Business Quant data shows ZTS's Restructuring Costs at $20.0 million in Q1 2026, $16.0 million in Q4 2025, and $4.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Alkermes	8.02 Bn	7.37 Bn	397.90 Mn

Download Data